TY - JOUR

T1 - Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe

T2 - systemic inflammation during co-infection and after treatment for schistosomiasis

AU - Erikstrup, Christian

AU - Kallestrup, Per

AU - Zinyama-Gutsire, Rutendo B L

AU - Gomo, Exnevia

AU - van Dam, Govert J

AU - Deelder, André M.

AU - Butterworth, Anthony E

AU - Pedersen, Bente Klarlund

AU - Ostrowski, Sisse R

AU - Gerstoft, Jan

AU - Ullum, Henrik

PY - 2008/9

Y1 - 2008/9

N2 - We previously reported that treatment for schistosomiasis in persons infected with human immunodeficiency virus 1 (HIV-1) attenuated HIV replication as measured by plasma HIV RNA. We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment. The cohort was composed of 378 persons who were or were not infected with HIV-1, Schistosoma haematobium, or S. mansoni. Schistosomiasis-infected persons were randomized to receive praziquantel (40 mg/kg) at baseline or at the three-month follow-up. sTNF-rII and IL-8 were positively associated with schistosomiasis intensity as measured by circulating anodic antigen (CAA), regardless of HIV status. Interleukin-10 was positively associated with CAA in HIV-negative participants. IL-8 levels were higher in S. mansoni-infected individuals. Treatment for schistosomiasis caused a decrease in levels of sTNF-rII (P < 0.05) and IL-10 (P < 0.001). Our results indicate that schistosomiasis treatment may attenuate HIV replication by decreasing systemic inflammation.

AB - We previously reported that treatment for schistosomiasis in persons infected with human immunodeficiency virus 1 (HIV-1) attenuated HIV replication as measured by plasma HIV RNA. We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment. The cohort was composed of 378 persons who were or were not infected with HIV-1, Schistosoma haematobium, or S. mansoni. Schistosomiasis-infected persons were randomized to receive praziquantel (40 mg/kg) at baseline or at the three-month follow-up. sTNF-rII and IL-8 were positively associated with schistosomiasis intensity as measured by circulating anodic antigen (CAA), regardless of HIV status. Interleukin-10 was positively associated with CAA in HIV-negative participants. IL-8 levels were higher in S. mansoni-infected individuals. Treatment for schistosomiasis caused a decrease in levels of sTNF-rII (P < 0.05) and IL-10 (P < 0.001). Our results indicate that schistosomiasis treatment may attenuate HIV replication by decreasing systemic inflammation.

KW - Adolescent

KW - Adult

KW - Cohort Studies

KW - Cross-Sectional Studies

KW - Cytokines

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Inflammation

KW - Interleukin-10

KW - Interleukin-8

KW - Male

KW - Middle Aged

KW - Praziquantel

KW - Receptors, Tumor Necrosis Factor, Type II

KW - Schistosomiasis

KW - Schistosomicides

KW - Zimbabwe

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

KW - Research Support, U.S. Gov't, P.H.S.

M3 - Journal article

C2 - 18784223

VL - 79

SP - 331

EP - 337

JO - Journal. National Malaria Society

JF - Journal. National Malaria Society

SN - 0002-9637

IS - 3

ER -